ArticleFrontiers in medicine2022
Different Trends in the Incidence and Mortality Rates of Prostate Cancer Between China and the USA: A Joinpoint and Age-Period-Cohort Analysis.
Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 24 citations in OpenAlex.
- Low follow-up rate after positive prostate cancer screening in southern China: a community-based cross-sectional survey with a prospective component.Frontiers in public health · 2026Article
- SLX1 silencing overcomes Olaparib resistance in metastatic castration-resistant prostate cancer by disrupting SLX4-mediated DNA repair complexes.Cancer biology & therapy · 2025Article
- Global trends in prostate cancer burden among adults aged 80 years and older from 1990 to 2021 based on the global burden of disease 2021.Discover oncology · 2025Article
- Advances in the treatment of metastatic prostate cancer in China.Cancer biology & medicine · 2025Article
- From obesity to inflammation: emerging frontiers in prostate cancer and metabolic syndrome studies.Translational andrology and urology · 2025Article
- Global burden of prostate cancer: age-period-cohort analysis from 1990 to 2021 and projections until 2040.World journal of surgical oncology · 2025Article
- A retrospective study of neoadjuvant novel hormonal therapy prior to radical prostatectomy for high-risk prostate cancer.Frontiers in oncology · 2025Article
- Prostate Cancer Mortality in Iranian Men During 1990-2021: An Age-Period-Cohort and Joinpoint Regression Analysis.Prostate cancer · 2025Article
- Burden of Carbon Monoxide Poisoning in Asian Countries From 1990 to 2021 and Its Projection Until 2030: An Analysis of the Global Burden of Disease Study 2021.Clinical epidemiology · 2025Article
- Enhanced precision in prostate surgery: determining key factors for rectal positive surgical margins through integrated imaging and clinical data analysis.Frontiers in surgery · 2025Article
- Global, regional, and national prevalence of prostate cancer from 1990 to 2021: a trend and health inequality analyses.Frontiers in public health · 2025Article
- Diagnostic utility of serum prostate-specific antigen and circulating inflammatory markers for differentiating prostate cancer from benign prostatic hyperplasia.American journal of cancer research · 2025Article
- Trends in Cancer Incidence and Potential Associated Factors in China.JAMA network open · 2024Article
- Exploring Prostate Cancer Incidence Trends and Age Change in Cancer Registration Areas of Jiangsu Province, China, 2009 to 2019.Current oncology (Toronto, Ont.) · 2024Article
- The disease burden of bladder cancer and its attributable risk factors in five Eastern Asian countries, 1990-2019: a population-based comparative study.BMC public health · 2024Article
- Temporal trends of breast cancer burden in the Western Pacific Region from 1990 to 2044: Implications from the Global Burden of Disease Study 2019.Journal of advanced research · 2024Article
- Article
- Identification of anoikis-related gene signatures and construction of the prognosis model in prostate cancer.Frontiers in pharmacology · 2024Article
- Global, regional, and national burden of multiple sclerosis from 1990 to 2019: Findings of global burden of disease study 2019.Frontiers in public health · 2023Article
- The mFrontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study used data from the Global Burden of Disease Study 2019 (GBD 2019) to determine the differences in the incidence and mortality of prostate cancer (PCa) between China and the USA from 1990 to 2019.
methodThe age-standardized incidence rates (ASIRs) and age-standardized death rates (ASDRs) in China and the USA from 1990 to 2019 were extracted from GBD 2019. Annual percentage changes and relative risks of ASIR and ASDR were calculated using joinpoint regression analysis and age-period-cohort models, respectively.
resultsThe ASIR of PCa in China continually increased from 1990 to 2019, while in the USA it increased from 1990 to 1994 and then continually decreased until 2015, and then slightly increased again until 2019. The ASDR in China did not change, and the trend of ASDR in the USA was similar to the trend of the ASIR in the USA. The incidence of PCa increased with age in China, but decreased after the age of 75 years in the USA. A period effect was present, with the risk of developing PCa increasing continuously over longer time periods. Those born later had a lower risk of PCa or death, indicating a cohort effect.
conclusionPCa is becoming more problematic for Chinese males. Disease trends in the USA indicate that large-scale screening may be beneficial and should be immediately implemented among high-risk groups in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.